Nadim | search
Click here to view Nadim news from 60+ newspapers.
Bookmark or Share- Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung CancerNeoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab-based neoadjuvant regimens have...
- Perioperative nivolumab results in favourable long-term ... - NatureNADIM is, to the best of our knowledge, the first trial to test a perioperative anti-PD-1 antibody in patients with resectable NSCLC 2.This open-label, multicentre, single-arm phase II trial ...
- Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell ...In this open-label, phase 2 trial, we randomly assigned patients with resectable stage IIIA or IIIB NSCLC to receive neoadjuvant nivolumab plus platinum-based chemotherapy (experimental group) or...
- Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell ...Non-small-cell lung cancer (NSCLC) is terminal in most patients with locally advanced stage disease. We aimed to assess the antitumour activity and safety of neoadjuvant chemoimmunotherapy for resectable stage IIIA NSCLC. This was an open-label, multicentre, single-arm phase 2 trial done at 18 hospitals in Spain.
- Perioperative chemotherapy and nivolumab in non-small-cell lung cancer ...Perioperative immunotherapy improves short-term outcomes in resectable non-small-cell lung cancer (NSCLC). We now report 5-year survival from the NADIM trial to assess its long-term benefit. NADIM was a multicentre, single-arm, phase 2 trial conducted across 18 hospitals in Spain.
More
